Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
出版年份 2014 全文链接
标题
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
作者
关键词
VEGF, Angiogenesis, Metastasis, Resistance, Microenvironment, Personalised medicine
出版物
ANGIOGENESIS
Volume 17, Issue 3, Pages 471-494
出版商
Springer Nature
发表日期
2014-02-01
DOI
10.1007/s10456-014-9420-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
- (2015) Terence C. Tang et al. NEOPLASIA
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis
- (2013) Benoit Beuselinck et al. ACTA ONCOLOGICA
- Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models
- (2013) Xiao-Dong Zhu et al. ANGIOGENESIS
- A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
- (2013) T. Powles et al. ANNALS OF ONCOLOGY
- Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
- (2013) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy
- (2013) N S Vasudev et al. BRITISH JOURNAL OF CANCER
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1
- (2013) Jia Lu et al. CANCER CELL
- Macrophage Regulation of Tumor Responses to Anticancer Therapies
- (2013) Michele De Palma et al. CANCER CELL
- A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
- (2013) E. Guerin et al. CANCER RESEARCH
- The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications
- (2013) G. G. Van den Eynden et al. CANCER RESEARCH
- Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
- (2013) Lin Cheng et al. CELL
- The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
- (2013) K. Sharpe et al. CLINICAL CANCER RESEARCH
- Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
- (2013) F. Collinson et al. CLINICAL CANCER RESEARCH
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- (2013) D. Maru et al. CLINICAL CANCER RESEARCH
- Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
- (2013) N. R. Smith et al. CLINICAL CANCER RESEARCH
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- (2013) Alfredo Carrato et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- (2013) John P. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
- (2013) Charlotte Anderberg et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Colorectal Cancer Cells Refractory to Anti-VEGF Treatment Are Vulnerable to Glycolytic Blockade due to Persistent Impairment of Mitochondria
- (2013) J. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Differential Therapeutic Effects of Anti-VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing
- (2013) D. Alishekevitz et al. MOLECULAR CANCER THERAPEUTICS
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- Drug rechallenge and treatment beyond progression—implications for drug resistance
- (2013) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
- (2013) Douglas W. McMillin et al. NATURE REVIEWS DRUG DISCOVERY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neuropilin signalling in vessels, neurons and tumours
- (2013) Claudio Raimondi et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
- (2012) J.-C. Soria et al. ANNALS OF ONCOLOGY
- CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
- (2012) T. Jiang et al. BLOOD
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
- (2012) B. Sitohy et al. CANCER RESEARCH
- The histological growth pattern of colorectal cancer liver metastases has prognostic value
- (2012) Gert G. Van den Eynden et al. CLINICAL & EXPERIMENTAL METASTASIS
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
- (2012) A. W. Griffioen et al. CLINICAL CANCER RESEARCH
- Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?
- (2012) J. P. B. O'Connor et al. CLINICAL CANCER RESEARCH
- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
- (2012) V. Moreno Garcia et al. CLINICAL CANCER RESEARCH
- Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
- (2012) A. McIntyre et al. CLINICAL CANCER RESEARCH
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- The history of adoption of hepatic resection for metastatic colorectal cancer: 1984–95
- (2012) D. Grünhagen et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?
- (2012) Hope S. Rugo JOURNAL OF CLINICAL ONCOLOGY
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
- (2012) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- (2012) Annamaria Rapisarda et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients
- (2012) Camillo Porta et al. ONCOLOGY
- Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
- (2012) Cornelia Schuster et al. PLoS One
- Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival
- (2012) T. Gruenberger et al. SURGICAL ONCOLOGY-OXFORD
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
- (2012) José R. Rossari et al. Journal of Oncology
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
- (2011) R. Wong et al. ANNALS OF ONCOLOGY
- Signal transduction by vascular endothelial growth factor receptors
- (2011) Sina Koch et al. BIOCHEMICAL JOURNAL
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration
- (2011) F Fan et al. BRITISH JOURNAL OF CANCER
- Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape
- (2011) E. di Tomaso et al. CANCER RESEARCH
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
- (2011) J.-L. Li et al. CANCER RESEARCH
- Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
- (2011) G. Nardo et al. CANCER RESEARCH
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
- (2011) Nicholas J. Robert et al. Clinical Breast Cancer
- Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2011) Katherine M. Krajewski et al. EUROPEAN UROLOGY
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- (2011) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
- (2011) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies
- (2011) Rodrigo Leite de Oliveira et al. MOLECULAR ASPECTS OF MEDICINE
- Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer
- (2011) Sònia Tugues et al. MOLECULAR ASPECTS OF MEDICINE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- (2011) Peter Carmeliet et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs
- (2011) R. Dienstmann et al. ONCOLOGIST
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
- (2010) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
- (2010) A A M van der Veldt et al. BRITISH JOURNAL OF CANCER
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
- (2010) Keith T. Flaherty et al. CANCER BIOLOGY & THERAPY
- CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies
- (2010) P.D. Nathan et al. CANCER BIOLOGY & THERAPY
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
- (2010) Carlos Bais et al. CELL
- Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
- (2010) Sara Van de Veire et al. CELL
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer
- (2010) Andrew R. Reynolds Dose-Response
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
- (2010) Iris Helfrich et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
- (2010) Lucia Ricci-Vitiani et al. NATURE
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT
- (2010) Laure S. Fournier et al. RADIOLOGY
- VEGF-B
- (2010) Xuri Li et al. Cell Adhesion & Migration
- The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases
- (2009) Ingrid M. E. Desar et al. ACTA ONCOLOGICA
- Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
- (2009) Pascal Wolter et al. ACTA ONCOLOGICA
- Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
- (2009) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
- (2009) B. Nordlinger et al. ANNALS OF ONCOLOGY
- Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
- (2009) Sonja Loges et al. CANCER CELL
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Intussusceptive microvascular growth in human glioma
- (2009) Beatrice Nico et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
- (2009) J. M. L. Ebos et al. CLINICAL CANCER RESEARCH
- Imaging glioma cell invasionin vivoreveals mechanisms of dissemination and peritumoral angiogenesis
- (2009) Frank Winkler et al. GLIA
- Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling
- (2009) Samuel A. Yousem HUMAN PATHOLOGY
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- The nuances of therapy
- (2009) Lee M. Ellis et al. NATURE
- Biomechanical regulation of blood vessel growth during tissue vascularization
- (2009) Witold W Kilarski et al. NATURE MEDICINE
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way
- (2009) Peter Carmeliet et al. Nature Reviews Clinical Oncology
- The Vascular Basement Membrane as “Soil” in Brain Metastasis
- (2009) W. Shawn Carbonell et al. PLoS One
- PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment
- (2009) Emmanuelle di Tomaso et al. PLoS One
- VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
- (2009) F. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation
- (2008) Ruslan Hlushchuk et al. AMERICAN JOURNAL OF PATHOLOGY
- Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
- (2008) Yuval Shaked et al. CANCER CELL
- Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer
- (2008) Elise Langenkamp et al. CELL AND TISSUE RESEARCH
- Functional significance of VEGFR-2 on ovarian cancer cells
- (2008) Whitney A. Spannuth et al. INTERNATIONAL JOURNAL OF CANCER
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
- (2008) Olwen M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- A role for VEGF as a negative regulator of pericyte function and vessel maturation
- (2008) Joshua I. Greenberg et al. NATURE
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
- (2008) Christian Stockmann et al. NATURE
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
- (2008) T. E. Hutson et al. ONCOLOGIST
- Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
- (2008) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of myeloid cells in tumor angiogenesis and growth
- (2008) Farbod Shojaei et al. TRENDS IN CELL BIOLOGY
- VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
- (2007) W Kimryn Rathmell et al. Expert Review of Anticancer Therapy
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now